Real-Time European Filings API. Request Access
TITAN PHARMACEUTICALS INC Logo

TITAN PHARMACEUTICALS INC

Develops a long-term drug delivery implant for treating chronic central nervous system disorders.

TTNP | US

Overview

Corporate Details

ISIN(s):
US8883146065
LEI:
Country:
United States of America
Address:
400 OYSTER POINT BLVD, 94080 SAN FRANCISCO
Website:
https://www.titanpharm.com/
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics for the treatment of select chronic diseases. The company's core technology is its clinically proven ProNeura® platform, a long-term, continuous drug delivery system. This platform is designed to deliver stable, non-fluctuating levels of medication for periods of up to one year from a single subcutaneous implant. Titan's research and development activities are focused on exploring new therapeutic applications for the ProNeura platform, with a primary emphasis on treating central nervous system disorders. In late 2023, the company announced a merger with Black Titan Corporation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all TITAN PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TITAN PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for TITAN PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Mabion S.A. Logo
Mabion S.A.
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
MACROGENICS INC
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
MADRIGAL PHARMACEUTICALS, INC.
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
Magle Chemoswed Holding AB
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
MAIA Biotechnology, Inc. Logo
MAIA Biotechnology, Inc.
Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.
United States of America
MAIA
Mainz BioMed N.V.
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
MANNKIND CORP
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
MARAVAI LIFESCIENCES HOLDINGS, INC.
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Marinomed Biotech AG
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Marker Therapeutics, Inc.
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR

Talk to a Data Expert

Have a question? We'll get back to you promptly.